Funded Project Details - FY2021
|Title:|| Inhibiting pathological TDP-43 phosphorylation as a therapeutic strategy for ALS|
Brian C. Kraemer
|Congressional District Code:
||Biomedical Laboratory R&D
|| April 2017 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
TAR DNA-binding protein 43 kDa (TDP-43) is the major aggregating disease protein in amyotrophic lateral sclerosis (ALS). Over 90% of ALS cases exhibit pathological lesions containing detergent insoluble deposits of phosphorylated, truncated, and ubiquitinated TDP-43 protein. TDP-43 phosphorylated at S409/410 (pS409/410) is the most consistent, robust, and specific neuropathological feature of ALS suggesting a phosphorylated TDP-43 (pTDP) mediated cascade of neurotoxicity. Furthermore pTDP has be...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.